CN1245981C - Liquid preparation made from pazufloxacin leucinocaine fed through eye in application of curing ophthalmic diseases and producing method - Google Patents
Liquid preparation made from pazufloxacin leucinocaine fed through eye in application of curing ophthalmic diseases and producing method Download PDFInfo
- Publication number
- CN1245981C CN1245981C CN 200310105857 CN200310105857A CN1245981C CN 1245981 C CN1245981 C CN 1245981C CN 200310105857 CN200310105857 CN 200310105857 CN 200310105857 A CN200310105857 A CN 200310105857A CN 1245981 C CN1245981 C CN 1245981C
- Authority
- CN
- China
- Prior art keywords
- parts
- injection
- water
- sodium
- pazufloxacin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 title claims abstract description 38
- 229960002625 pazufloxacin Drugs 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000007788 liquid Substances 0.000 title abstract description 12
- 201000010099 disease Diseases 0.000 title description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 7
- MLHBDHJHNDJBLI-UHFFFAOYSA-N leucinocaine Chemical compound CCN(CC)C(CC(C)C)COC(=O)C1=CC=C(N)C=C1 MLHBDHJHNDJBLI-UHFFFAOYSA-N 0.000 title 1
- 229950006997 leucinocaine Drugs 0.000 title 1
- 238000003756 stirring Methods 0.000 claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 35
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000008215 water for injection Substances 0.000 claims abstract description 25
- 239000000243 solution Substances 0.000 claims abstract description 20
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 17
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000011780 sodium chloride Substances 0.000 claims abstract description 15
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims abstract description 14
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 14
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims abstract description 13
- 229910000397 disodium phosphate Inorganic materials 0.000 claims abstract description 13
- 235000019800 disodium phosphate Nutrition 0.000 claims abstract description 13
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 9
- 235000019253 formic acid Nutrition 0.000 claims abstract description 7
- 229940098779 methanesulfonic acid Drugs 0.000 claims abstract description 7
- 238000010438 heat treatment Methods 0.000 claims abstract description 5
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 5
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 4
- 238000007689 inspection Methods 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 25
- 239000000052 vinegar Substances 0.000 claims description 17
- 235000021419 vinegar Nutrition 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 15
- 238000012856 packing Methods 0.000 claims description 15
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 238000004659 sterilization and disinfection Methods 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 239000011265 semifinished product Substances 0.000 claims description 13
- 239000003889 eye drop Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000003643 water by type Substances 0.000 claims description 10
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 8
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 235000011091 sodium acetates Nutrition 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 abstract description 2
- 229960000583 acetic acid Drugs 0.000 abstract 4
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 abstract 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 abstract 3
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010010741 Conjunctivitis Diseases 0.000 abstract 1
- 208000001860 Eye Infections Diseases 0.000 abstract 1
- 229920002385 Sodium hyaluronate Polymers 0.000 abstract 1
- 238000004500 asepsis Methods 0.000 abstract 1
- 229960004106 citric acid Drugs 0.000 abstract 1
- 235000015165 citric acid Nutrition 0.000 abstract 1
- 208000011323 eye infectious disease Diseases 0.000 abstract 1
- 206010023332 keratitis Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 abstract 1
- 229960002668 sodium chloride Drugs 0.000 abstract 1
- 229940010747 sodium hyaluronate Drugs 0.000 abstract 1
- 235000011121 sodium hydroxide Nutrition 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 7
- 206010059866 Drug resistance Diseases 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 150000007660 quinolones Chemical class 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 229960003376 levofloxacin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 210000002164 blood-aqueous barrier Anatomy 0.000 description 1
- 230000004420 blood-aqueous barrier Effects 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310105857 CN1245981C (en) | 2003-10-27 | 2003-10-27 | Liquid preparation made from pazufloxacin leucinocaine fed through eye in application of curing ophthalmic diseases and producing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310105857 CN1245981C (en) | 2003-10-27 | 2003-10-27 | Liquid preparation made from pazufloxacin leucinocaine fed through eye in application of curing ophthalmic diseases and producing method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1539422A CN1539422A (en) | 2004-10-27 |
CN1245981C true CN1245981C (en) | 2006-03-22 |
Family
ID=34333895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310105857 Expired - Lifetime CN1245981C (en) | 2003-10-27 | 2003-10-27 | Liquid preparation made from pazufloxacin leucinocaine fed through eye in application of curing ophthalmic diseases and producing method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1245981C (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115919761B (en) * | 2023-01-29 | 2023-07-21 | 浙江莎普爱思药业股份有限公司 | Pazufloxacin mesylate liquid preparation and preparation method thereof |
CN116270448B (en) * | 2023-02-24 | 2024-01-30 | 浙江莎普爱思药业股份有限公司 | Preparation method of pazufloxacin mesylate liquid preparation |
-
2003
- 2003-10-27 CN CN 200310105857 patent/CN1245981C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1539422A (en) | 2004-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ye et al. | Mild temperature photothermal assisted anti-bacterial and anti-inflammatory nanosystem for synergistic treatment of post-cataract surgery endophthalmitis | |
CN106074568A (en) | One is used for preventing and treat cataractous ophthalmic preparation and preparation method thereof | |
WO2008148292A1 (en) | An ophthalmic, otic or nasal composition and its use | |
AU2019212565B2 (en) | Ophthalmic pharmaceutical composition, preparation method therefor and application thereof | |
JPWO2008053982A1 (en) | Allergy treatment composition | |
CN108853016A (en) | A kind of ophthalmic solution sodium eye drops and preparation method thereof | |
CN101278908B (en) | Eye drop capable of significantly increasing medicament effect | |
CN1245981C (en) | Liquid preparation made from pazufloxacin leucinocaine fed through eye in application of curing ophthalmic diseases and producing method | |
CN1302812C (en) | Transmission system of medicine containing trehalose and hyaluronic acid for eye part and its preparation method | |
CN1823772A (en) | New pranoprofen eye drops and its preparation method | |
CN101396333A (en) | Eye in-situ gel of chiral anti-glaucoma medicine L-3alpha alkyla acyloxy-6belta alkyla acyloxy tropane and preparation method thereof | |
EA035966B1 (en) | Use of a pharmaceutical composition for topical application in treating lacrimal system and anterior segment of the eye disorders | |
CN102008488B (en) | Triamcinolone acetonide ophthalmic preparation and preparation method thereof | |
CN101077347A (en) | Multifunctional membrane used for glaucoma post-operation and preparation method thereof | |
RU2485939C1 (en) | Disulfiram and taurine-containing ophthalmological medication in form of eye drops | |
CN112891326B (en) | Natamycin-loaded alginic acid gel medicine film and preparation method thereof | |
MX2008008701A (en) | Sterilized peritoneal dialysis solutions containing heparin. | |
CN1397272A (en) | In-vivo gel preparatino able to be dropped in eyes and its preparing process | |
CN1132584C (en) | Myopia treating eye drop | |
CN103977008B (en) | Gel for eye containing Dorzolamide and timolol and preparation method thereof | |
CN112220749B (en) | Mizoribine and application of composition containing mizoribine | |
CN1562030A (en) | Gatiflxacin eye gels based on HPMC medium and its preparing method | |
CN1424043A (en) | Kakonein eye drops | |
RU2284181C2 (en) | Pharmaceutical composition for prophylaxis of ophthalmological infections | |
EP4364722A1 (en) | Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: ZHEJIANG SHAPUAIS PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: ZHEJIANG PINGHU SHAPUAISI PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: 314200 Zhejiang Pinghu City Road Bridge Lumian towel Patentee after: Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Address before: 314200 Zhejiang Pinghu City Road Bridge Lumian towel Patentee before: Zhejiang Pinghu Shapuaisi Pharmaceutical Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20110510 Address after: 314200 Zhejiang Province, Pinghu City Road Bridge Lumian towel Patentee after: ZHEJIANG SHAPUAISI PHARMACY Ltd. Address before: 314200 Zhejiang Pinghu City Road Bridge Lumian towel Patentee before: Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 314200 Zhejiang province Pinghu Xinming Road Economic Development Zone No. 1588 Patentee after: ZHEJIANG SHAPUAISI PHARMACY Ltd. Address before: 314200 Zhejiang Province, Pinghu City Road Bridge Lumian towel Patentee before: ZHEJIANG SHAPUAISI PHARMACY Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060322 |